“Vaccines, combined with other public health measures, bring the end of an acute phase of the pandemic and the rebuilding of economies within reach,” he noted.
Kluge said vaccine supplies would be very limited at first and that countries must decide who gets priority, though the WHO also cited “growing consensus” that first recipients should be older people, medical workers and people with other diseases.
US and EU regulators are reviewing the same data on Pfizer's vaccine trials, but have not given their approval yet.
The WHO has already received data from Pfizer and BioNTech on the vaccine and was reviewing it for “possible listing for emergency use” that could be a benchmark for other nations’ use.
As we reported earlier, Pfizer Company has reduced the plans on the production of the vaccine against coronavirus after facing difficulties.
Initially, it was planned to release 100 million doses; however, soon, the number of doses was reduced up to 50 million doses.
The reduction was explained by the fact that the enterprise lacks raw material due to the prolonged establishment of the supply chain.